search
Back to results

A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)

Primary Purpose

Myocardial Infarction

Status
Terminated
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
Tenecteplase
PCI
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Myocardial Infarction

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients giving informed consent Patients with a large acute myocardial infarction randomised within 6 hours of symptom onset Patients scheduled to undergo primary PCI Patients reaching the cath lab not before 60 min and not later than 3 hours after randomisation (Otherwise the patients fulfill the usual selection criteria for thrombolytic treatment and PCI) Exclusion Criteria: None

Sites / Locations

  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site

Outcomes

Primary Outcome Measures

Death or cardiogenic shock or congestive heart failure within 90 days

Secondary Outcome Measures

Death or cardiogenic shock or congestive heart failure within 30 days
Cardiogenic shock or congestive heart failure within 90 days
Death
Cardiogenic shock
Reinfarction
Repeat target vessel revascularisation (TVR)
Rehospitalisation for congestive heart failure
Rehospitalisation for cardiogenic shock
Rehospitalisation for other cardiac reasons
Congestive heart failure
N-terminal pro-brain natriuretic peptide (NT pro-BNP)
Disabling stroke
Total stroke
Rehospitalisation for stroke or ICH (intrancranial haemorrhage)

Full Information

First Posted
September 9, 2005
Last Updated
October 28, 2013
Sponsor
Boehringer Ingelheim
Collaborators
Genentech, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT00168792
Brief Title
A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)
Official Title
A Phase IIIb - IV, Randomised, Open Label Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early PCI as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction. ASSENT 4 PCI (Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction.)
Study Type
Interventional

2. Study Status

Record Verification Date
October 2013
Overall Recruitment Status
Terminated
Study Start Date
November 2003 (undefined)
Primary Completion Date
July 2006 (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Boehringer Ingelheim
Collaborators
Genentech, Inc.

4. Oversight

5. Study Description

Brief Summary
To show whether addition of thrombolytic treatment by a single bolus injection of tenecteplase prior to early standard PCI (percutaneous coronary intervention) will improve the clinical outcome in patients with large acute myocardial infarcts as compared to primary PCI alone.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myocardial Infarction

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1671 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Tenecteplase
Intervention Type
Procedure
Intervention Name(s)
PCI
Primary Outcome Measure Information:
Title
Death or cardiogenic shock or congestive heart failure within 90 days
Time Frame
90 days
Secondary Outcome Measure Information:
Title
Death or cardiogenic shock or congestive heart failure within 30 days
Time Frame
30 days
Title
Cardiogenic shock or congestive heart failure within 90 days
Time Frame
90 days
Title
Death
Time Frame
90 days
Title
Cardiogenic shock
Time Frame
90 days
Title
Reinfarction
Time Frame
90 days
Title
Repeat target vessel revascularisation (TVR)
Time Frame
90 days
Title
Rehospitalisation for congestive heart failure
Time Frame
90 days
Title
Rehospitalisation for cardiogenic shock
Time Frame
90 days
Title
Rehospitalisation for other cardiac reasons
Time Frame
90 days
Title
Congestive heart failure
Time Frame
90 days
Title
N-terminal pro-brain natriuretic peptide (NT pro-BNP)
Time Frame
90 days
Title
Disabling stroke
Time Frame
90 days
Title
Total stroke
Time Frame
90 days
Title
Rehospitalisation for stroke or ICH (intrancranial haemorrhage)
Time Frame
90 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients giving informed consent Patients with a large acute myocardial infarction randomised within 6 hours of symptom onset Patients scheduled to undergo primary PCI Patients reaching the cath lab not before 60 min and not later than 3 hours after randomisation (Otherwise the patients fulfill the usual selection criteria for thrombolytic treatment and PCI) Exclusion Criteria: None
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim Study Coordinator
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
Boehringer Ingelheim Investigational Site
City
Little Rock
State/Province
Arkansas
Country
United States
Facility Name
Boehringer Ingelheim Investigational Site
City
Fort Lauderdale
State/Province
Florida
Country
United States
Facility Name
Boehringer Ingelheim Investigational Site
City
St. Petersburg
State/Province
Florida
Country
United States
Facility Name
Boehringer Ingelheim Investigational Site
City
Tampa
State/Province
Florida
Country
United States
Facility Name
Boehringer Ingelheim Investigational Site
City
Macan
State/Province
Georgia
Country
United States
Facility Name
Boehringer Ingelheim Investigational Site
City
Detroit
State/Province
Michigan
Country
United States
Facility Name
Boehringer Ingelheim Investigational Site
City
Omaha
State/Province
Nebraska
Country
United States
Facility Name
Boehringer Ingelheim Investigational Site
City
Providence
State/Province
Rhode Island
Country
United States
Facility Name
Boehringer Ingelheim Investigational Site
City
Feldkirch
Country
Austria
Facility Name
Boehringer Ingelheim Investigational Site
City
St. Pölten
Country
Austria
Facility Name
Boehringer Ingelheim Investigational Site
City
Wien
Country
Austria
Facility Name
Boehringer Ingelheim Investigational Site
City
Wr. Neustadt
Country
Austria
Facility Name
Boehringer Ingelheim Investigational Site
City
Aalst
Country
Belgium
Facility Name
Boehringer Ingelheim Investigational Site
City
Antwerpen
Country
Belgium
Facility Name
Boehringer Ingelheim Investigational Site
City
Bonheiden
Country
Belgium
Facility Name
Boehringer Ingelheim Investigational Site
City
Brugge
Country
Belgium
Facility Name
Boehringer Ingelheim Investigational Site
City
Brussel
Country
Belgium
Facility Name
Boehringer Ingelheim Investigational Site
City
Bruxelles / Anderlecht
Country
Belgium
Facility Name
Boehringer Ingelheim Investigational Site
City
Bruxelles
Country
Belgium
Facility Name
Boehringer Ingelheim Investigational Site
City
Charleroi
Country
Belgium
Facility Name
Boehringer Ingelheim Investigational Site
City
Genk
Country
Belgium
Facility Name
Boehringer Ingelheim Investigational Site
City
Gent
Country
Belgium
Facility Name
Boehringer Ingelheim Investigational Site
City
Gilly
Country
Belgium
Facility Name
Boehringer Ingelheim Investigational Site
City
Huy
Country
Belgium
Facility Name
Boehringer Ingelheim Investigational Site
City
La Louvière
Country
Belgium
Facility Name
Boehringer Ingelheim Investigational Site
City
Leuven
Country
Belgium
Facility Name
Boehringer Ingelheim Investigational Site
City
Liège-Angleur
Country
Belgium
Facility Name
Boehringer Ingelheim Investigational Site
City
Liège
Country
Belgium
Facility Name
Boehringer Ingelheim Investigational Site
City
Namur/Bouge
Country
Belgium
Facility Name
Boehringer Ingelheim Investigational Site
City
Namur
Country
Belgium
Facility Name
Boehringer Ingelheim Investigational Site
City
Roeselare
Country
Belgium
Facility Name
Boehringer Ingelheim Investigational Site
City
Blumenau - SC
Country
Brazil
Facility Name
Boehringer Ingelheim Investigational Site
City
Curitiba - PR
Country
Brazil
Facility Name
Boehringer Ingelheim Investigational Site
City
Marília - SP
Country
Brazil
Facility Name
Boehringer Ingelheim Investigational Site
City
Passo Fundo - RS
Country
Brazil
Facility Name
Boehringer Ingelheim Investigational Site
City
Porto Alegre - RS
Country
Brazil
Facility Name
Boehringer Ingelheim Investigational Site
City
São Paulo - SP
Country
Brazil
Facility Name
Boehringer Ingelheim Investigational Site
City
Victoria
State/Province
British Columbia
Country
Canada
Facility Name
Boehringer Ingelheim Investigational Site
City
Saint-Foy
State/Province
Ontario
Country
Canada
Facility Name
Boehringer Ingelheim Investigational Site
City
Sudbury
State/Province
Ontario
Country
Canada
Facility Name
Boehringer Ingelheim Investigational Site
City
Montreal
State/Province
Quebec
Country
Canada
Facility Name
Boehringer Ingelheim Investigational Site
City
Regina
State/Province
Saskatchewan
Country
Canada
Facility Name
Boehringer Ingelheim Investigational Site
City
Saskatoon
State/Province
Saskatchewan
Country
Canada
Facility Name
Boehringer Ingelheim Investigational Site
City
Pardubice
Country
Czech Republic
Facility Name
Boehringer Ingelheim Investigational Site
City
Prague 4-Krc
Country
Czech Republic
Facility Name
Boehringer Ingelheim Investigational Site
City
Prague 5
Country
Czech Republic
Facility Name
Boehringer Ingelheim Investigational Site
City
Aulnay sous Bois
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Brest
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Caen
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Châteauroux
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Clermont-Ferrand
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Colmar
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Créteil
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Lille
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Lorient
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Lyon
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Marseille
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Massy
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Metz
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Montfermeil
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Montpellier
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Nice
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Nîmes
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Paris
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Perpignan
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Pontoise
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Saint Etienne
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Strasbourg
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Bad Friedrichshall
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Bad Kreuznach
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Bassum
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Bautzen
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Berlin-Lichtenberg
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Berlin
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Bingen
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Bonn
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Boppard
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Bremen
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Böblingen
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Dresden
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Fürstenfeldbruck
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Gransee
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Hameln
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Heidelberg
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Jena
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Kassel
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Kiel
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Koblenz
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Korbach
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Köln
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Leipzig
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Ludwigsburg
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Mannheim
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Minden
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Möckmühl
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Mönchengladbach
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
München
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Offenbach
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Paderborn
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Ravensburg
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Rüdesheim am Rhein
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Schwalmstadt
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Sömmerda
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Wiesbaden
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Öhringen
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Athens
Country
Greece
Facility Name
Boehringer Ingelheim Investigational Site
City
Heraklion
Country
Greece
Facility Name
Boehringer Ingelheim Investigational Site
City
Ioannina
Country
Greece
Facility Name
Boehringer Ingelheim Investigational Site
City
Nea Efkarpia/ Thessaloniki
Country
Greece
Facility Name
Boehringer Ingelheim Investigational Site
City
Nikaea, Piraeus
Country
Greece
Facility Name
Boehringer Ingelheim Investigational Site
City
Rio, Patra
Country
Greece
Facility Name
Boehringer Ingelheim Investigational Site
City
Thessaloniki
Country
Greece
Facility Name
Boehringer Ingelheim Investigational Site
City
Balatonfüred
Country
Hungary
Facility Name
Boehringer Ingelheim Investigational Site
City
Budapest
Country
Hungary
Facility Name
Boehringer Ingelheim Investigational Site
City
Debrecen
Country
Hungary
Facility Name
Boehringer Ingelheim Investigational Site
City
Pécs
Country
Hungary
Facility Name
Boehringer Ingelheim Investigational Site
City
Galway
Country
Ireland
Facility Name
Boehringer Ingelheim Investigational Site
City
Alessandria
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
Bassano del Grappa
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
Caserta
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
Catania
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
Cremona
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
Firenze
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
Genova
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
Lecce
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
Lecco
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
Loreto Mare (NA)
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
Mantova
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
Massa
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
Messina
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
Mirano (VE)
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
Monza
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
Novara
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
Padova
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
Palermo
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
Pesaro
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
Potenza
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
Ravenna
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
Rho (mi)
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
Roma
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
Salerno
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
San Donato Milanese
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
Sassari
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
Torino
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
Udine
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
Varese
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
Zingonia (bg)
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
col. Doctores
Country
Mexico
Facility Name
Boehringer Ingelheim Investigational Site
City
Col. Granada
Country
Mexico
Facility Name
Boehringer Ingelheim Investigational Site
City
Col. Magdalena de las Salinas
Country
Mexico
Facility Name
Boehringer Ingelheim Investigational Site
City
Col. Sección XVI, Deleg.
Country
Mexico
Facility Name
Boehringer Ingelheim Investigational Site
City
Col. Valle Verde
Country
Mexico
Facility Name
Boehringer Ingelheim Investigational Site
City
Mèxico, D.F.
Country
Mexico
Facility Name
Boehringer Ingelheim Investigational Site
City
Bergen
Country
Norway
Facility Name
Boehringer Ingelheim Investigational Site
City
Oslo
Country
Norway
Facility Name
Boehringer Ingelheim Investigational Site
City
Katowice-Ochojec
Country
Poland
Facility Name
Boehringer Ingelheim Investigational Site
City
Katowice
Country
Poland
Facility Name
Boehringer Ingelheim Investigational Site
City
Krakow
Country
Poland
Facility Name
Boehringer Ingelheim Investigational Site
City
Lodz
Country
Poland
Facility Name
Boehringer Ingelheim Investigational Site
City
Lublin
Country
Poland
Facility Name
Boehringer Ingelheim Investigational Site
City
Opole
Country
Poland
Facility Name
Boehringer Ingelheim Investigational Site
City
Poznan
Country
Poland
Facility Name
Boehringer Ingelheim Investigational Site
City
Warsaw
Country
Poland
Facility Name
Boehringer Ingelheim Investigational Site
City
Wroclaw
Country
Poland
Facility Name
Boehringer Ingelheim Investigational Site
City
Zabrze
Country
Poland
Facility Name
Boehringer Ingelheim Investigational Site
City
Almada
Country
Portugal
Facility Name
Boehringer Ingelheim Investigational Site
City
Amadora
Country
Portugal
Facility Name
Boehringer Ingelheim Investigational Site
City
Carnaxide
Country
Portugal
Facility Name
Boehringer Ingelheim Investigational Site
City
Coimbra
Country
Portugal
Facility Name
Boehringer Ingelheim Investigational Site
City
Lisboa
Country
Portugal
Facility Name
Boehringer Ingelheim Investigational Site
City
Porto
Country
Portugal
Facility Name
Boehringer Ingelheim Investigational Site
City
Vila Nova de Gaia
Country
Portugal
Facility Name
Boehringer Ingelheim Investigational Site
City
Bangkok
Country
Thailand
Facility Name
Boehringer Ingelheim Investigational Site
City
Chiangmai
Country
Thailand
Facility Name
Boehringer Ingelheim Investigational Site
City
Ankara
Country
Turkey
Facility Name
Boehringer Ingelheim Investigational Site
City
Istanbul
Country
Turkey
Facility Name
Boehringer Ingelheim Investigational Site
City
Izmir
Country
Turkey

12. IPD Sharing Statement

Citations:
PubMed Identifier
16488800
Citation
Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet. 2006 Feb 18;367(9510):569-78. doi: 10.1016/S0140-6736(06)68147-6.
Results Reference
result
PubMed Identifier
21545942
Citation
Zalewski J, Bogaerts K, Desmet W, Sinnaeve P, Berger P, Grines C, Danays T, Armstrong P, Van de Werf F. Intraluminal thrombus in facilitated versus primary percutaneous coronary intervention: an angiographic substudy of the ASSENT-4 PCI (Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention) trial. J Am Coll Cardiol. 2011 May 10;57(19):1867-73. doi: 10.1016/j.jacc.2010.10.061.
Results Reference
derived
PubMed Identifier
20562693
Citation
Jarai R, Huber K, Bogaerts K, Sinnaeve PR, Ezekowitz J, Ross AM, Zeymer U, Armstrong PW, Van de Werf FJ; ASSENT-4 PCI investigators. Prediction of cardiogenic shock using plasma B-type natriuretic peptide and the N-terminal fragment of its pro-hormone [corrected] concentrations in ST elevation myocardial infarction: an analysis from the ASSENT-4 Percutaneous Coronary Intervention Trial. Crit Care Med. 2010 Sep;38(9):1793-801. doi: 10.1097/CCM.0b013e3181eaaf2a. Erratum In: Crit Care Med. 2010 Dec;38(12):2430.
Results Reference
derived
Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1123/1123.12_statement.pdf
Description
Related Info
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1123/1123.12_U06-1687.pdf
Description
Related Info
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1123/1123.12_literature.pdf
Description
Related Info

Learn more about this trial

A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)

We'll reach out to this number within 24 hrs